Spotlight on PSMA as a new theranostic biomarker for bladder cancer

Abstract Bladder cancer (BCa) patients are diagnosed by cytology and cystoscopy. However, these diagnostic tests bear some limitations. We sought for reliable biomarkers to better determine BCa extension. Prostate-specific membrane antigen (PSMA) appears to fulfill this requirement in prostate cance...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria Maddalena Tumedei, Sara Ravaioli, Federica Matteucci, Monica Celli, Ugo De Giorgi, Roberta Gunelli, Maurizio Puccetti, Giovanni Paganelli, Sara Bravaccini
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9e48e4bb4424421c8efc0070bd91a8d6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9e48e4bb4424421c8efc0070bd91a8d6
record_format	dspace
spelling	oai:doaj.org-article:9e48e4bb4424421c8efc0070bd91a8d62021-12-02T16:49:12ZSpotlight on PSMA as a new theranostic biomarker for bladder cancer10.1038/s41598-021-89160-02045-2322https://doaj.org/article/9e48e4bb4424421c8efc0070bd91a8d62021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89160-0https://doaj.org/toc/2045-2322Abstract Bladder cancer (BCa) patients are diagnosed by cytology and cystoscopy. However, these diagnostic tests bear some limitations. We sought for reliable biomarkers to better determine BCa extension. Prostate-specific membrane antigen (PSMA) appears to fulfill this requirement in prostate cancer but its role in BCa has not been established yet. We then analyzed 87 bladder tissue samples from 74 patients assessing PSMA expression by immunohistochemistry. The median PSMA expression, exclusively found in tumor neovasculature, in terms of H-score significantly differed between non-tumor samples and tumor samples (p = 0.00288) showing a higher neovasculature-related PSMA expression. No differences were observed in relation to tumor type, grade and stage. BCa neovasculature-related PSMA overexpression may be useful in defining the degree of extension of the neoplasm. In addition, testing PSMA expression by immunohistochemistry may hold theranostic implications both considering anti-angiogenesis agents and radio-labelled PSMA ligands for intracavitary radionuclide therapy. In our opinion, BCa neovasculature-related PSMA overexpression may be considered an apt target for anti-angiogenesis and radionuclide treatment in BCa, once the evaluation of tumor-retention time for the appropriateness of long half-life therapeutic PSMA ligands as radionuclide treatment will be performed.Maria Maddalena TumedeiSara RavaioliFederica MatteucciMonica CelliUgo De GiorgiRoberta GunelliMaurizio PuccettiGiovanni PaganelliSara BravacciniNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Maria Maddalena Tumedei Sara Ravaioli Federica Matteucci Monica Celli Ugo De Giorgi Roberta Gunelli Maurizio Puccetti Giovanni Paganelli Sara Bravaccini Spotlight on PSMA as a new theranostic biomarker for bladder cancer
description	Abstract Bladder cancer (BCa) patients are diagnosed by cytology and cystoscopy. However, these diagnostic tests bear some limitations. We sought for reliable biomarkers to better determine BCa extension. Prostate-specific membrane antigen (PSMA) appears to fulfill this requirement in prostate cancer but its role in BCa has not been established yet. We then analyzed 87 bladder tissue samples from 74 patients assessing PSMA expression by immunohistochemistry. The median PSMA expression, exclusively found in tumor neovasculature, in terms of H-score significantly differed between non-tumor samples and tumor samples (p = 0.00288) showing a higher neovasculature-related PSMA expression. No differences were observed in relation to tumor type, grade and stage. BCa neovasculature-related PSMA overexpression may be useful in defining the degree of extension of the neoplasm. In addition, testing PSMA expression by immunohistochemistry may hold theranostic implications both considering anti-angiogenesis agents and radio-labelled PSMA ligands for intracavitary radionuclide therapy. In our opinion, BCa neovasculature-related PSMA overexpression may be considered an apt target for anti-angiogenesis and radionuclide treatment in BCa, once the evaluation of tumor-retention time for the appropriateness of long half-life therapeutic PSMA ligands as radionuclide treatment will be performed.
format	article
author	Maria Maddalena Tumedei Sara Ravaioli Federica Matteucci Monica Celli Ugo De Giorgi Roberta Gunelli Maurizio Puccetti Giovanni Paganelli Sara Bravaccini
author_facet	Maria Maddalena Tumedei Sara Ravaioli Federica Matteucci Monica Celli Ugo De Giorgi Roberta Gunelli Maurizio Puccetti Giovanni Paganelli Sara Bravaccini
author_sort	Maria Maddalena Tumedei
title	Spotlight on PSMA as a new theranostic biomarker for bladder cancer
title_short	Spotlight on PSMA as a new theranostic biomarker for bladder cancer
title_full	Spotlight on PSMA as a new theranostic biomarker for bladder cancer
title_fullStr	Spotlight on PSMA as a new theranostic biomarker for bladder cancer
title_full_unstemmed	Spotlight on PSMA as a new theranostic biomarker for bladder cancer
title_sort	spotlight on psma as a new theranostic biomarker for bladder cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9e48e4bb4424421c8efc0070bd91a8d6
work_keys_str_mv	AT mariamaddalenatumedei spotlightonpsmaasanewtheranosticbiomarkerforbladdercancer AT sararavaioli spotlightonpsmaasanewtheranosticbiomarkerforbladdercancer AT federicamatteucci spotlightonpsmaasanewtheranosticbiomarkerforbladdercancer AT monicacelli spotlightonpsmaasanewtheranosticbiomarkerforbladdercancer AT ugodegiorgi spotlightonpsmaasanewtheranosticbiomarkerforbladdercancer AT robertagunelli spotlightonpsmaasanewtheranosticbiomarkerforbladdercancer AT mauriziopuccetti spotlightonpsmaasanewtheranosticbiomarkerforbladdercancer AT giovannipaganelli spotlightonpsmaasanewtheranosticbiomarkerforbladdercancer AT sarabravaccini spotlightonpsmaasanewtheranosticbiomarkerforbladdercancer
_version_	1718383412304150528

Spotlight on PSMA as a new theranostic biomarker for bladder cancer

Ejemplares similares